Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.

<h4>Objectives</h4>Metabolic changes in the substantia nigra of patients with Parkinson's disease were previously investigated in different molecular-pathological examinations. The aim of our study was the in vivo measurement of these alterations using three-dimensional magnetic res...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adriane Gröger, Rupert Kolb, Rita Schäfer, Uwe Klose
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3a8ed90ca6314fb193729682521030a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3a8ed90ca6314fb193729682521030a2
record_format	dspace
spelling	oai:doaj.org-article:3a8ed90ca6314fb193729682521030a22021-11-18T08:38:37ZDopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.1932-620310.1371/journal.pone.0084081https://doaj.org/article/3a8ed90ca6314fb193729682521030a22014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24416192/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objectives</h4>Metabolic changes in the substantia nigra of patients with Parkinson's disease were previously investigated in different molecular-pathological examinations. The aim of our study was the in vivo measurement of these alterations using three-dimensional magnetic resonance spectroscopic imaging.<h4>Methods</h4>21 patients with Parkinson's disease and 24 controls were examined using magnetic resonance spectroscopic imaging at 3 Tesla. The spectra of rostral and caudal substantia nigra regions were analyzed using LCModel. For spectral fitting, an adjusted basis data set with pathology-specific metabolites and macromolecules was used to better reproduce the in vivo spectra. To assess differences between both groups more accurately, especially in metabolites at lower concentrations, group-averaged spectra were evaluated in addition to the analysis of individual data.<h4>Results</h4>We found significantly decreased N-acetylaspartate, choline, creatine, myo-inositol, glutathione and dopamine concentrations in patients with Parkinson's disease compared to controls, whereas glutamine+glutamate, γ-aminobutyric acid, and homovanillic acid were slightly increased. According to anatomical features, clear differences in the biochemical profiles were found between rostral and caudal substantia nigra voxels in both groups.<h4>Conclusions</h4>Reduced N-acetylaspartate and dopamine concentrations result from progressive degeneration of dopamine-producing neurons within the substantia nigra pars compacta. Decreased creatine levels can be interpreted as impaired energy metabolism due to mitochondrial dysfunction. Lower glutathione concentrations might be a cause or consequence of oxidative stress. Furthermore, slightly increased glutamine+glutamate and γ-aminobutyric acid levels are expected based on post mortem data in Parkinson's disease. To the best of our knowledge, this is the first non-invasive confirmation of these metabolic changes.Adriane GrögerRupert KolbRita SchäferUwe KlosePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 1, p e84081 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Adriane Gröger Rupert Kolb Rita Schäfer Uwe Klose Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
description	<h4>Objectives</h4>Metabolic changes in the substantia nigra of patients with Parkinson's disease were previously investigated in different molecular-pathological examinations. The aim of our study was the in vivo measurement of these alterations using three-dimensional magnetic resonance spectroscopic imaging.<h4>Methods</h4>21 patients with Parkinson's disease and 24 controls were examined using magnetic resonance spectroscopic imaging at 3 Tesla. The spectra of rostral and caudal substantia nigra regions were analyzed using LCModel. For spectral fitting, an adjusted basis data set with pathology-specific metabolites and macromolecules was used to better reproduce the in vivo spectra. To assess differences between both groups more accurately, especially in metabolites at lower concentrations, group-averaged spectra were evaluated in addition to the analysis of individual data.<h4>Results</h4>We found significantly decreased N-acetylaspartate, choline, creatine, myo-inositol, glutathione and dopamine concentrations in patients with Parkinson's disease compared to controls, whereas glutamine+glutamate, γ-aminobutyric acid, and homovanillic acid were slightly increased. According to anatomical features, clear differences in the biochemical profiles were found between rostral and caudal substantia nigra voxels in both groups.<h4>Conclusions</h4>Reduced N-acetylaspartate and dopamine concentrations result from progressive degeneration of dopamine-producing neurons within the substantia nigra pars compacta. Decreased creatine levels can be interpreted as impaired energy metabolism due to mitochondrial dysfunction. Lower glutathione concentrations might be a cause or consequence of oxidative stress. Furthermore, slightly increased glutamine+glutamate and γ-aminobutyric acid levels are expected based on post mortem data in Parkinson's disease. To the best of our knowledge, this is the first non-invasive confirmation of these metabolic changes.
format	article
author	Adriane Gröger Rupert Kolb Rita Schäfer Uwe Klose
author_facet	Adriane Gröger Rupert Kolb Rita Schäfer Uwe Klose
author_sort	Adriane Gröger
title	Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
title_short	Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
title_full	Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
title_fullStr	Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
title_full_unstemmed	Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
title_sort	dopamine reduction in the substantia nigra of parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/3a8ed90ca6314fb193729682521030a2
work_keys_str_mv	AT adrianegroger dopaminereductioninthesubstantianigraofparkinsonsdiseasepatientsconfirmedbyinvivomagneticresonancespectroscopicimaging AT rupertkolb dopaminereductioninthesubstantianigraofparkinsonsdiseasepatientsconfirmedbyinvivomagneticresonancespectroscopicimaging AT ritaschafer dopaminereductioninthesubstantianigraofparkinsonsdiseasepatientsconfirmedbyinvivomagneticresonancespectroscopicimaging AT uweklose dopaminereductioninthesubstantianigraofparkinsonsdiseasepatientsconfirmedbyinvivomagneticresonancespectroscopicimaging
_version_	1718421493781626880

Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.

Ejemplares similares